Literature DB >> 6450431

The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.

R A White, P Workman, J M Brown.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6450431

Source DB:  PubMed          Journal:  Radiat Res        ISSN： 0033-7587            Impact factor:   2.841


× No keyword cloud information.
  10 in total

1.  KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.

Authors:  K Sasai; Y Shibamoto; M Takahashi; L Zhou; H Hori; H Nagasawa; T Shibata; S Inayama; M Abe
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Acquired factor V deficiency in the setting of mercaptopurine therapy for acute lymphoblastic leukemia.

Authors:  Kelsey Uminski; Roy Khalife; Jill Fulcher; Lisa Duffett; Tzu-Fei Wang; Alan Tinmouth
Journal:  Ann Hematol       Date:  2021-10-06       Impact factor: 3.673

3.  Structure-pharmacokinetic relationships for misonidazole analogues in mice.

Authors:  P Workman; J M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

4.  Correlation of partitioning of nitroimidazoles in the n-octanol/saline and liposome systems with pharmacokinetic parameters and quantitative structure-activity relationships (QSAR).

Authors:  G V Betageri; J A Rogers
Journal:  Pharm Res       Date:  1989-05       Impact factor: 4.200

Review 5.  Nitroimidazoles and imaging hypoxia.

Authors:  A Nunn; K Linder; H W Strauss
Journal:  Eur J Nucl Med       Date:  1995-03

6.  2-Nitroimidazole potentiation of nitrosourea induced cytotoxicity in subcutaneous implants of rat 9L brain tumor cells.

Authors:  K H Wong; C A Wallen; K T Wheeler
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

7.  A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.

Authors:  K Sasai; Y Shibamoto; M Takahashi; M Abe; J Wang; L Zhou; S Nishimoto; T Kagiya
Journal:  Jpn J Cancer Res       Date:  1989-11

8.  Preclinical pharmacokinetics of benznidazole.

Authors:  P Workman; R A White; M I Walton; L N Owen; P R Twentyman
Journal:  Br J Cancer       Date:  1984-09       Impact factor: 7.640

9.  Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.

Authors:  D W Siemann
Journal:  Br J Cancer       Date:  1982-02       Impact factor: 7.640

10.  Enhancing effect of misonidazole on the response of the RIF-1 tumour to cyclophosphamide.

Authors:  M P Law; D G Hirst; J M Brown
Journal:  Br J Cancer       Date:  1981-08       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.